Regístrese
Buscar en
Revista Iberoamericana de Micología
Toda la web
Inicio Revista Iberoamericana de Micología Drug susceptibility profile of Candida glabrata clinical isolates from Iran and ...
Información de la revista
Vol. 35. Núm. 2.
Páginas 88-91 (Abril - Junio 2018)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Visitas
534
Vol. 35. Núm. 2.
Páginas 88-91 (Abril - Junio 2018)
Original article
DOI: 10.1016/j.riam.2018.01.002
Acceso a texto completo
Drug susceptibility profile of Candida glabrata clinical isolates from Iran and genetic resistant mechanisms to caspofungin
Perfil de sensibilidad antifúngica de aislamientos clínicos de Candida glabrata de Irán y mecanismos genéticos de resistencia a la caspofungina
Visitas
534
Saeid Amanlooa, Masoomeh Shams-Ghahfarokhia,
Autor para correspondencia
, Mohammad Ghahrib, Mehdi Razzaghi-Abyanehc
a Department of Mycology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran 14115-331, Iran
b Department of Biological Sciences, Faculty of Basic Sciences, Imam Hossein University, Tehran, Iran
c Department of Mycology, Pasteur Institute of Iran, Tehran 13164, Iran
Este artículo ha recibido
534
Visitas
Información del artículo
Resumen
Texto completo
Bibliografía
Descargar PDF
Estadísticas
Figuras (1)
Tablas (2)
Table 1. Distribution of MICs for 50 clinical isolates of C. glabrata.
Table 2. Polymorphic nucleotide sites in hotspot areas of FKS1 and FKS2 compared to the genome database sequences of C. glabrata CBS 138.
Mostrar másMostrar menos
Abstract
Background

Candida glabrata is a yeast that can cause hazardous fungal infections with high mortality and drug resistance.

Aims

The aim of this study was to determine the profile of drug susceptibility in clinical isolates of C. glabrata and review the resistance mechanisms to caspofungin.

Methods

A total of 50 C. glabrata clinical isolates from Iran were tested for in vitro susceptibilities to amphotericin B, caspofungin, fluconazole and voriconazole. To investigate the mechanism of resistance to caspofungin, hotspot areas of FKS1 and FKS2 genes were sequenced and gene expression profile was evaluated.

Results

All the isolates were susceptible to amphotericin B and caspofungin. Fluconazole resistance was exhibited in four isolates. In addition, only one isolate was resistant to voriconazole. FKS2 with 12 point mutations showed more mutations compared to FKS1 that had only two mutations. All substitutions were synonymous. FKS genes were expressed at comparable levels (no statistical significance) in caspofungin-treated and non-treated cultures.

Conclusions

The silent mutations in the hotspot areas of FKS genes and inconsiderable changes in gene expression were not associated with increased MIC (0.25μg/ml). Other mechanisms of resistance which include mutations outside the hotspot area of FKS genes could be involved in a slight increase of MIC, and they should be identified through complete FKS gene sequencing.

Keywords:
Candida glabrata
Candidiasis
Drug susceptibility
Echinocandins
Caspofungin
Resumen
Antecedentes

Candida glabrata es una levadura que puede causar infecciones de una alta mortalidad, además de presentar resistencia a los tratamientos antifúngicos.

Objetivos

El objetivo del presente estudio fue determinar la sensibilidad a diversos antifúngicos de aislamientos clínicos de C. glabrata, además de revisar sus mecanismos de resistencia a la caspofungina.

Métodos

Se estudió la sensibilidad in vitro de 50 aislamientos clínicos de C. glabrata de Irán a los antifúngicos anfotericina B, caspofungina, fluconazol y voriconazol. Con el fin de investigar el mecanismo de resistencia a la caspofungina se secuenciaron secciones hotspot de los genes FKS1 y FKS2, y se evaluó su grado de expresión.

Resultados

Todos los aislamientos fueron sensibles a la anfotericina B y a la caspofungina. Cuatro aislamientos fueron resistentes al fluconazol. Un solo aislamiento presentó resistencia al voriconazol. FKS2 mostró un mayor número de mutaciones (12) que FKS1, donde se encontraron solo dos; todas las sustituciones fueron silentes. No se encontró diferencia estadística en la expresión de los genes FKS entre los aislamientos crecidos en cultivo con caspofungina y los que crecieron en cultivo sin la presencia del antifúngico.

Conclusiones

Las mutaciones silentes en las areas hotspot de los genes FKS y los cambios insignificantes en la expresión de los genes no se asociaron con un incremento de la MIC (0,25μg/ml). Otros mecanismos de resistencia, como mutaciones fuera de las áreas hotspot de los genes FKS, podrían conllevar un ligero aumento de la MIC, pero para determinar claramente su papel debería realizarse una secuenciación completa de los genes FKS.

Palabras clave:
Candida glabrata
Candidiasis
Sensibilidad antifúngica
Equinocandinas
Caspofungina
Texto completo

Candida species are the most common cause of invasive mycotic diseases in hospitalized patients, and approximately 10% of all nosocomial bloodstream infections worldwide are attributed to this genus.5 Over the past few decades, C. glabrata has emerged as a prominent and potentially multidrug-resistant Candida species,25 such that this organism is the third most common cause of bloodstream candidiasis in Iran.5

Echinocandins are considered to be active drugs against C. glabrata and have been introduced as the first-line treatment of infections associated with C. glabrata,12,15 although several studies have increasingly reported resistance to echinocandins in Candida isolates.6,11,20,23–25 Nevertheless, despite the increasing use of echinocandins, resistance to these drugs is still rare.17,18 Molecular mechanisms of resistance to echinocandins have been previously described.7 In most cases, the molecular mechanisms of resistance are associated with mutations in hotspot areas of FKS genes, and the MIC depends on the position of the mutation and the type of substitution in the translated amino acid.8,13,19,20 The actual prevalence of FKS mutations and echinocandins resistance in each region depends on the local epidemiological and population structure studies. In addition, due to the clinical significance of C. glabrata and the few studies on echinocandins resistance conducted in Iran, this study aimed to determine the profile of drug resistance in clinical isolates of C. glabrata, and review the resistance mechanisms to caspofungin.

Materials and methods

In this study, 50 clinical isolates of C. glabrata, which had been previously reported, were used.2 Isolates were tested for in vitro susceptibilities to amphotericin B, caspofungin, fluconazole and voriconazole using broth microdilution method as described by the Clinical Laboratory Standards Institute (CLSI) M27-A3 and M27-A4 document guidelines.3,4 Thereafter, isolates that had the highest MIC against caspofungin were used for subsequent analyses. The conventional phenol-chloroform extraction method was used for DNA extraction.10 Then hotspot 1 and hotspot 2 regions of FKS1 and FKS2 genes were amplified and sequenced in both forward and reverse directions with the same primer used for the PCRs.23 Sequencing reactions were performed using BigDye terminator technology (ABI, Foster City, CA) with an ABI Prism 3730 (ABI series) DNA sequencer. Nucleotide sequences were defined by alignment of forward and reverse sequences using MEGA software, version 5.2, and polymorphic sites were confirmed by visual examination of the chromatograms. Then results were compared with DNA database of GenBank (XM-446406 for FKS1 gene and XM-448401 for FKS2 gene).

First, C. glabrata isolates were grown overnight at 35°C in YPD broth medium containing caspofungin, with shaking at 150rpm, and cell cultures without drug treatment served as controls. Total RNA was extracted using RNX-plus kit according to the manufacturer's instruction (SinaClon BioScience Co., Karaj, Iran). Gene expression profile was performed using Two-step SYBR green quantitative reverse transcription-PCR (qRT-PCR) with Applied Biosystems Step One Plus Real-Time PCR System.6 All experiments were performed in triplicate and the evaluation of gene expression was done using Pfaffl method.16 The C. glabrata URA3 gene (GenBank accession no, AY771209) was used for normalization.6

Results and discussion

As shown in Table 1, a total of 41 isolates (82%) were susceptible to fluconazole, five isolates (10%) were susceptible-dose-dependent (MIC=32μg/ml), and four isolates (8%) with MIC=64μg/ml were determined as resistant to fluconazole. In addition, 46 isolates (92%) were susceptible to voriconazole, three isolates (6%) with MIC=2μg/ml were considered susceptible-dose-dependent, and one isolate with MIC=4μg/ml was resistant. All isolates were susceptible to amphotericin B and MIC of all of them was under the epidemiological cutoff (2μg/ml). As shown in Table 1, no isolate resistant to caspofungin was found, but hotspot areas of FKS1 and FKS2 genes of two isolates with MIC of 0.25μg/ml and one isolate with MIC of 0.0625μg/ml were sequenced (GenBank accession numbers MF538706 to MF538717) and compared to the genome database sequences (GenBank accession number XM_446406 for FKS1 and XM_448401 for FKS2). Sequence analysis revealed that all mutations were silent. Nucleotide polymorphic sites and subsequent amino acid substitutions are shown in Table 2. The highest number of polymorphisms occurred in the nucleotide sequence of FKS2 hotspot 1. There were 10 nucleotide replacements and all changes were synonymous. In the hotspot 2 area of FKS2 gene, two variations were also recorded and, finally, in hotspot 1, two sites of FKS1 gene and one nucleotide change were observed. As shown in Fig. 1 the expression level of FKS genes remained relatively stable compared to the URA3, and gene expression in treated and non-treated cultures was not statistically significant.

Table 1.

Distribution of MICs for 50 clinical isolates of C. glabrata.

Antifungals  MIC (μg/ml)
  0.008  0.016  0.0313  0.0625  0.125  0.25  0.5  16  32  64 
Fluconazole  11  12 
Voriconazole  12 
Caspofungin  17  18 
Amphotericin B  10  13  16 

Results are presented as the number of C. glabrata isolates with MIC in each two-fold serial dilution of the tested antifungals (concentration: 0.008–64μg/ml).

Table 2.

Polymorphic nucleotide sites in hotspot areas of FKS1 and FKS2 compared to the genome database sequences of C. glabrata CBS 138.

Isolate no.  F1H1  F1H2  F2H1F2H2
  2343  4314  1941  1956  1959  2046  2119  2191  2358  2370  2442  2469  4104  4195 
CBS 138 
ST-46 
ST-75 
S14 

F: FKS gene, H: hotspot.

The numbers represent the positions of the variable nucleotides relating to the fragments sequenced.

Fig. 1.

Relative expression of three different C. glabrata FKS genes compared to C. glabrata URA3 gene. Significant relative gene expressions have been marked with an asterisk.

(0,09MB).

In this study, no resistance to AMB or caspofungin was found among the studied isolates, and these drugs are recommended in the treatment of C. glabrata infections. All fluconazole-resistant isolates showed low MICs to caspofungin and amphotericin B. On the other hand, three isolates showed high MICs to both fluconazole and voriconazole. Although the sensitivity of C. glabrata to voriconazole is high, an increasing resistance to this drug is possible according to the ECV index and the expanded use of voriconazole in the general population.

There are conflicting results from different studies on echinocandins resistance. Some studies reported that despite the increasing use of echinocandins, resistance to these drugs is still rare.17,18 Other studies demonstrate the emergence of Candida isolates resistant to echinocandins.6,11,20,23–25 Despite the increasing number of reports that have mentioned echinocandins resistance,6,11,20,23–25 this study show that C. glabrata has high sensitivity to echinocandins, and the sensitivity rate to caspofungin was 100%. Considering the low use of echinocandins, such as caspofungin, in Iran such result was hence predictable. The constant exposure to antibiotics can cause the development of drug resistance. In this study, as well as in previous reports, it has also been demonstrated that echinocandins resistance can occur under conditions of exposure to the drug.23 Shields et al. reported that in clinical isolates of C. glabrata, any mutation in FKS genes is associated with prior exposure to echinocandins.22 Alexander et al. also showed that any previous treatment with echinocandins in patients with candidaemia is a significant predictor of FKS mutations in C. glabrata.1

The gene expression level was not statistically different in the treated and non-treated states. FKS mutation rate in C. glabrata has been reported in the range of 3–18%.1,22FKS2 mutations in this species are about two times higher in comparison to FKS1 mutations.9 We found 12 mutations in FKS2 (10 point mutations in hotspot 1, and 2 mutations in hotspot 2) and only 2 mutations in FKS1. All substitutions were synonymous and protein coding was not changed. Therefore, any slight increase in the MIC of the studied isolates would be related to mutations in areas outside the hotspot of FKS genes, and this should be identified through the complete sequencing of FKS gene. Some researchers believe that identifying mutations in FKS genes is the most accurate method for predicting treatment failure with echinocandins.13,19 In most cases, the MIC value in mutant strains was markedly higher than that in wild type strains; a new indicator of clinical interpretive breakpoints distinguishes between different FKS mutations based on their clinical relevance and is also used to predict the response to the treatment.1 Overall, in vitro susceptibility tests are useful in predicting treatment response, therefore it is recommended in high-risk patients. Antifungal susceptibility tests should be routinely conducted,14,21 and echinocandins should be used with caution against Candida species.

Conflict of interests

The authors declare they have no conflict of interest.

Acknowledgments

We would like to express our gratitude to the Research Deputy of Tarbiat Modares University for funding our research.

References
[1]
B.D. Alexander, M.D. Johnson, C.D. Pfeiffer, C. Jiménez-Ortigosa, J. Catania, R. Booker, et al.
Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations.
Clin Infect Dis, 56 (2013), pp. 1724-1732
[2]
S. Amanloo, M. Shams-Ghahfarokhi, M. Ghahri, M. Razzaghi-Abyaneh.
Genotyping of clinical isolates of Candida glabrata from Iran by multilocus sequence typing and determination of population structure and drug resistance profile.
Med Mycol, 56 (2018), pp. 207-215
[3]
CLSI.
(CLSI) CaLSI: Reference Method For Broth Dilution Antifungal Susceptibility Testing of Yeasts, Approved standard M27-A3.
2nd ed., Clinical Laboratory Standard Institute, (2008),
[4]
CLSI.
(CLSI) CaLSI: Reference method for broth dilution antifungal susceptibility testing of yeasts, Approved standard M27-S4.
Clinical Laboratory Standard Institute, (2012),
Fourth informational supplement
[5]
N. Fathi, R. Mohammadi, M.A. Tabatabaiefar, M. Ghahri, S.Z. Sadrossadati.
Sequence-identification of Candida species isolated from candidemia.
Adv Biomed Res, 5 (2016), pp. 150
[6]
G. Garcia-Effron, S.K. Katiyar, S. Park, T.D. Edlind, D.S. Perlin.
A naturally occurring proline-to-alanine amino acid change in Fks1p in Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis accounts for reduced echinocandin susceptibility.
Antimicrob Agents Chemother, 52 (2008), pp. 2305-2312
[7]
G. Garcia-Effron, S. Lee, S. Park, J.D. Cleary, D.S. Perlin.
Effect of Candida glabrata FKS1 and FKS2 mutations on echinocandin sensitivity and kinetics of 1, 3-β-d-glucan synthase: implication for the existing susceptibility breakpoint.
Antimicrob Agents Chemother, 53 (2009), pp. 3690-3699
[8]
G. Garcia-Effron, D.J. Chua, J.R. Tomada, J. DiPersio, D.S. Perlin, M. Ghannoum, et al.
Novel FKS mutations associated with echinocandin resistance in Candida species.
Antimicrob Agents Chemother, 54 (2010), pp. 2225-2227
[9]
L. Lan, J. Xu.
Multiple gene genealogical analyses suggest divergence and recent clonal dispersal in the opportunistic human pathogen Candida guilliermondii.
Microbiology, 152 (2006), pp. 1539-1549
[10]
Müller F-MC, K.E. Werner, M. Kasai, A. Francesconi, S.J. Chanock, T.J. Walsh.
Rapid extraction of genomic DNA from medically important yeasts and filamentous fungi by high-speed cell disruption.
J Clin Microbiol, 36 (1998), pp. 1625-1629
[11]
P. Paderu, G. Garcia-Effron, S. Balashov, G. Delmas, S. Park, D.S. Perlin.
Serum differentially alters the antifungal properties of echinocandin drugs.
Antimicrob Agents Chemother, 51 (2007), pp. 2253-2256
[12]
P.G. Pappas, C.A. Kauffman, D. Andes, D.K. Benjamin, T.F. Calandra, J.E. Edwards, et al.
Clinical practice guidelines for the management candidiasis: 2009 update by the Infectious Diseases Society of America.
Clin Infect Dis, 48 (2009), pp. 503-535
[13]
D.S. Perlin.
Resistance to echinocandin-class antifungal drugs.
Drug Resist Update, 10 (2007), pp. 121-130
[14]
D.S. Perlin.
Echinocandin resistance, susceptibility testing and prophylaxis: implications for patient management.
Drugs, 74 (2014), pp. 1573-1585
[15]
M.A. Pfaller, D.J. Diekema.
Epidemiology of invasive candidiasis: a persistent public health problem.
Clin Microbiol Rev, 20 (2007), pp. 133-163
[16]
M. Pfaller, S. Messer, L. Boyken, S. Tendolkar, R. Hollis, D. Diekema.
Selection of a surrogate agent (fluconazole or voriconazole) for initial susceptibility testing of posaconazole against Candida spp.: results from a global antifungal surveillance program.
J Clin Microbiol, 46 (2008), pp. 551-559
[17]
M. Pfaller, L. Boyken, R. Hollis, J. Kroeger, S. Messer, S. Tendolkar, et al.
Use of epidemiological cutoff values to examine 9-year trends in susceptibility of Candida species to anidulafungin, caspofungin, and micafungin.
J Clin Microbiol, 49 (2011), pp. 624-629
[18]
M. Pfaller, M. Castanheira, S. Lockhart, A. Ahlquist, S. Messer, R. Jones.
Frequency of decreased susceptibility and resistance to echinocandins among fluconazole-resistant bloodstream isolates of Candida glabrata.
J Clin Microbiol, 50 (2012), pp. 1199-1203
[19]
C.D. Pham, C.B. Bolden, R.J. Kuykendall, S.R. Lockhart.
Development of a Luminex-based multiplex assay for detection of mutations conferring resistance to echinocandins in Candida glabrata.
J Clin Microbiol, 52 (2014), pp. 790-795
[20]
I. Pottier, S. Gente, J.-P. Vernoux, M. Guéguen.
Safety assessment of dairy microorganisms: Geotrichum candidum.
Int J Food Microbiol, 126 (2008), pp. 327-332
[21]
D. Shah, R. Yau, J. Weston, T. Lasco, M. Salazar, H. Palmer, et al.
Evaluation of antifungal therapy in patients with candidaemia based on susceptibility testing results: implications for antimicrobial stewardship programmes.
J Antimicrob Chemother, (2011),
dkr244
[22]
R.K. Shields, M.H. Nguyen, E.G. Press, A.L. Kwa, S. Cheng, C. Du, et al.
The presence of an FKS mutation rather than MIC is an independent risk factor for failure of echinocandin therapy among patients with invasive candidiasis due to Candida glabrata.
Antimicrob Agents Chemother, 56 (2012), pp. 4862-4869
[23]
G.R. Thompson, N.P. Wiederhold, A.C. Vallor, N.C. Villareal, J.S. Lewis, T.F. Patterson.
Development of caspofungin resistance following prolonged therapy for invasive candidiasis secondary to Candida glabrata infection.
Antimicrob Agents Chemother, 52 (2008), pp. 3783-3785
[24]
N.P. Wiederhold, L.K. Najvar, R. Bocanegra, D. Molina, M. Olivo, J.R. Graybill.
In vivo efficacy of anidulafungin and caspofungin against Candida glabrata and association with in vitro potency in the presence of sera.
Antimicrob Agents Chemother, 51 (2007), pp. 1616-1620
[25]
A.J. Zimbeck, N. Iqbal, A.M. Ahlquist, M.M. Farley, L.H. Harrison, T. Chiller, et al.
FKS mutations and elevated echinocandin MIC values among Candida glabrata isolates from US population-based surveillance.
Antimicrob Agents Chemother, 54 (2010), pp. 5042-5047
Copyright © 2018. Asociación Española de Micología
Opciones de artículo
Herramientas
es en pt
Política de cookies Cookies policy Política de cookies
Utilizamos cookies propias y de terceros para mejorar nuestros servicios y mostrarle publicidad relacionada con sus preferencias mediante el análisis de sus hábitos de navegación. Si continua navegando, consideramos que acepta su uso. Puede cambiar la configuración u obtener más información aquí. To improve our services and products, we use "cookies" (own or third parties authorized) to show advertising related to client preferences through the analyses of navigation customer behavior. Continuing navigation will be considered as acceptance of this use. You can change the settings or obtain more information by clicking here. Utilizamos cookies próprios e de terceiros para melhorar nossos serviços e mostrar publicidade relacionada às suas preferências, analisando seus hábitos de navegação. Se continuar a navegar, consideramos que aceita o seu uso. Você pode alterar a configuração ou obter mais informações aqui.